Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of TS-143 in Healthy Males
NCT03591133Phase 1Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- Dec 2015
- Primary completion
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TS-143 in anemia (6 arms), sponsored by Taisho Pharmaceutical. Primary endpoints: Incidence of adverse events at 8 days, Plasma concentrations of unchanged form at 72 hours and 2 more. Started Dec 2015; status: completed.
02
Drugs
TS-143
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03591133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591133.